Trials / Completed
CompletedNCT05870670
A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men
Investigation of Pharmacokinetics, Safety, and Tolerability of Multiple Subcutaneous Doses of NNC0519-0130 in Japanese and Non-Japanese Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
NNC0519-0130 is a new medicine which may possibly help participants with type 2 diabetes. This study, will look into how safe the new medicine NNC0519-0130 is, and we will measure its concentrations in the blood and look at its effects. This study will last for a maximum of 22 weeks and Japanese and Non-Japanese male participants will be included.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NNC0519-0130 | Administered subcutaneously. |
| DRUG | Placebo | Administered subcutaneously. |
Timeline
- Start date
- 2023-05-15
- Primary completion
- 2023-10-07
- Completion
- 2023-10-16
- First posted
- 2023-05-23
- Last updated
- 2025-06-18
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05870670. Inclusion in this directory is not an endorsement.